Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Deanna Merrill, PharmD, MBA, AAHIVP

Medical Affairs Scientific Director, Research
ViiV Healthcare

Disclosure(s): ViiV Healthcare: Salaried employee, Stocks/Bonds

Poster(s):

1278 - Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET
1279 - Real World Treatment Experience of Treatment-Naïve People with HIV who Initiated Treatment with Single Tablet Dolutegravir/Lamivudine in a Test and Treat setting in the US.
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET
1288 - US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND)
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET